Zinc Acetate Hydrate Supplementation versus Polaprezinc Supplementation for Improving Hypozincemia in Hemodialysis Patients: A Randomized Clinical Trial

Figure 4

Changes in the number of patients who continued zinc supplementation and in the mean zinc dose in the ZAH and PPZ groups. (a, b) Changes in the number of patients who continued zinc supplementation versus those who had discontinued zinc supplementation at each observation point in the ZAH group (a) and the PPZ group (b). (c) Changes in the mean zinc dose administered in the ZAH and PPZ groups based on the number of patients who continued zinc supplementation with either the initial dose or the reduced dose. (d) Changes in the mean administered dose per kg body weight in the ZAH and PPZ groups. In the ZAH group, the average dose after 20 weeks is 44.44 mg, which is significantly lower than the initial dose (50 mg). Meanwhile, there are no significant changes in the drug dose in the PPZ group. Zinc administration is reduced or discontinued more frequently in the ZAH group than in the PPZ group throughout the study period.

(a)

(b)

(c)

(d)